SecBot SecBot
8-K ·Filed May 4, 2026

MIRM

Mirum Pharmaceuticals, Inc.
BULLISH
Impact 6/10
Horizonmonths Processed6mo ago SEC0001193125-26-202609
8-K context-dependent: Items 8.01
Actionable Insight ▲ Bullish

The strong Phase 2b data materially de-risks volixibat's regulatory path in PSC. Monitor for the pre-NDA meeting outcome and any updates on the NDA submission timeline. The VANTAGE PBC readout in Q1 2027 adds a near-term pipeline catalyst.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$105.79
T+0 close · May 4, 2026 · via day close
Latest settled
+1.68%
T+60 · $107.57
Vs SPY
−0.17%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 4 $105.79entry
  2. T+1 · 7mo ago +0.02%α −0.78% · $105.81
  3. T+5 · 6mo ago +0.36%α −2.58% · $106.17
  4. T+20 · 6mo ago −8.94%α −14.59% · $96.33
  5. T+60 · 4mo ago +1.68%α −0.17% · $107.57
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Mirum Pharmaceuticals announced positive Phase 2b results for volixibat in PSC, meeting the primary endpoint with high statistical significance (p<0.0001) and a robust placebo-adjusted improvement in pruritus. The company plans a pre-NDA meeting with the FDA in summer 2026 and an NDA submission in H2 2026, positioning volixibat as a potential first treatment for cholestatic pruritus in PSC.

Key Facts

  • Primary endpoint met in VISTAS Phase 2b study of volixibat in PSC (p<0.0001).
  • Placebo-adjusted improvement of 1.64 points on Adult ItchRO scale.
  • 55.6% of volixibat patients achieved 2-point reduction vs 26.3% for placebo (p=0.0019).
  • Pre-NDA meeting with FDA scheduled for summer 2026; NDA submission planned H2 2026.
  • Safety profile consistent with IBAT inhibition; GI and liver enzyme elevations observed.
  • Topline data from VANTAGE Phase 2b study in PBC expected Q1 2027.

Financial Impact

No financial figures reported; positive Phase 2b data supports regulatory advancement and potential to address an unmet medical need.

Risk Factors

  • Safety signals including GI adverse events and liver enzyme elevations may raise regulatory concerns.
  • NDA submission and FDA approval are not guaranteed; additional trials or data may be required.
  • Competition from other therapies in development for PSC-related pruritus.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
94% bullish (17 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-202609
Document: 0001193125-26-202609-index-headers.html0001193125-26-202609
Document: 0001193125-26-202609-index.html0001193125-26-202609
Document: 0001193125-26-202609.txt0001193125-26-202609

US Market Status

Market Closed · Opens in 8h 37m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 4, 2026